Summary: Creative Biolabs provides a novel strategy that utilizes meditope technology to help clients develop customized antibody-drug conjugates (ADCs). In this methodology, the generation of meditope-enabled antibodies by site-specific carving is the core technique. Generally speaking, “Lego-like” cave sites are created on a monoclonal antibody (mAb) by switching out a few amino acid residues using antibody engineering and the resulted antibody is able to trap geometrically compliment meditopes, without the need for chemical conjugation. By adjusting and optimizing our meditope-enabled antibodies, a stable, non-covalent, yet site-specific conjugation can be achieved, resulting in the production of homogeneous ADC products with a predictable drug-to-antibody ratio (DAR). Creative Biolabs applies innovative meditope technology for customized ADC preparation services https://www.creative-biolabs.com/adc/meditope-technology-based-conjugation.htm
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
